Earnings summaries and quarterly performance for Ardent Health.
Executive leadership at Ardent Health.
Board of directors at Ardent Health.
ER
Edmondo Robinson
Detailed
Director
EH
Ellen Havdala
Detailed
Director
MS
Mark Sotir
Detailed
Chairman of the Board
PB
Peter Bulgarelli
Detailed
Director
PB
Peter Bynoe
Detailed
Director
RS
Rahul Sen
Detailed
Director
RW
Rob Webb
Detailed
Director
RA
Robert A. DeMichiei
Detailed
Director
SC
Suzanne Campion
Detailed
Director
WG
William Goodyear
Detailed
Director
Research analysts who have asked questions during Ardent Health earnings calls.
Benjamin Hendrix
RBC Capital Markets
4 questions for ARDT
Also covers: ACHC, ADUS, AHCO +25 more
BR
Benjamin Rossi
JPMorgan Chase & Co.
4 questions for ARDT
Also covers: AMED, AVAH, CON +7 more
CH
Craig Hettenbach
Morgan Stanley
4 questions for ARDT
Also covers: ACCD, AMWL, DH +10 more
MG
Matthew Gillmor
KeyCorp
4 questions for ARDT
Also covers: ACHC, ADUS, ALHC +11 more
AH
Ann Hynes
Mizuho Financial Group
2 questions for ARDT
Also covers: BTSG, CI, CNC +17 more
BM
Benjamin Mayo
Leerink Partners
2 questions for ARDT
Also covers: ACHC, AGL, AMED +10 more
JG
Joanna Gajuk
Bank of America
2 questions for ARDT
Also covers: ACHC, ADUS, AGL +21 more
SF
Scott Fidel
Stephens Inc.
2 questions for ARDT
Also covers: ACHC, ADUS, ALHC +17 more
TG
Timothy Greaves
Loop Capital Markets LLC
2 questions for ARDT
Also covers: PRCH, WEAV
Jason Cassorla
Guggenheim Partners
1 question for ARDT
Also covers: ACHC, CI, CYH +8 more
KF
Kevin Fischbeck
Bank of America
1 question for ARDT
Also covers: AMN, CCRN, CI +9 more
Raj Kumar
Stephens
1 question for ARDT
Also covers: ACHC, ADUS, AVAH +7 more
Whit Mayo
Leerink Partners
1 question for ARDT
Also covers: ACHC, AHCO, ALHC +11 more
Recent press releases and 8-K filings for ARDT.
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Accounting Changes
Financial Restatement
- A securities class action lawsuit has been filed against Ardent Health (ARDT) and certain executives following the company's "disastrous Q3 2025 financial results".
- The complaint alleges Ardent misled investors about its revenue recognition systems and the adequacy of its professional liability reserves.
- In Q3 2025, Ardent transitioned to a new accounting method, which led to a $42.6 million reduction in revenue and a $47.2 million increase in professional liability reserves.
- This news caused Ardent's share price to drop $4.75 (-33%).
- The class period for investors who purchased securities and suffered substantial losses is between July 18, 2024, and November 12, 2025.
3 days ago
Ardent Health Faces Securities Class Action Over Alleged Accounting Deception
ARDT
Legal Proceedings
Accounting Changes
Financial Restatement
- A securities class action lawsuit has been filed against Ardent Health, Inc. (ARDT) and certain executives by Hagens Berman, alleging investors were misled about the company's revenue recognition systems and professional liability reserves.
- The lawsuit covers a class period from July 18, 2024, to November 12, 2025, with a lead plaintiff deadline of March 9, 2026.
- Allegations state that Ardent did not primarily rely on detailed reviews for accounts receivable collectability, instead utilizing a 180-day cliff at which point an account became fully reserved.
- On November 12, 2025, Ardent revealed a Q3 2025 accounting method transition, which led to a $42.6 million revenue reduction and a $47.2 million increase in professional liability reserves.
- Following this news, Ardent's share price tumbled $4.75 (-33%) the next day.
5 days ago
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Accounting Changes
Financial Restatement
- A securities class action lawsuit has been filed against Ardent Health, Inc. (ARDT) following its Q3 2025 financial disclosures.
- The lawsuit alleges that adverse accounting adjustments, totaling approximately $90 million, were revealed, causing the stock to tumble over 33% in mid-November.
- These adjustments included a $42.6 million decrease in revenue and a $47.2 million increase in professional liability reserves for the three months ended September 30, 2025.
- The complaint further alleges that Ardent's leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves.
- The class period for the lawsuit is July 18, 2024, to November 12, 2025, with the Lead Plaintiff Deadline set for March 9, 2026.
Jan 15, 2026, 8:39 PM
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Accounting Changes
Profit Warning
- A securities class action lawsuit has been filed against Ardent Health, Inc. (ARDT) following its Q3 2025 financial disclosures.
- The lawsuit alleges adverse accounting adjustments totaling approximately $90 million, which included a $42.6 million decrease in revenue due to a change in accounting estimate for accounts receivable collectability and a $47.2 million increase in professional liability reserves.
- These disclosures caused Ardent's stock to tumble over 33% in mid-November.
- The class period for the lawsuit is from July 18, 2024, to November 12, 2025, with a lead plaintiff deadline of March 9, 2026.
Jan 13, 2026, 11:49 PM
Ardent Health Faces Class Action Lawsuit Over Alleged Misleading Statements
ARDT
Legal Proceedings
Financial Restatement
Profit Warning
- A class action lawsuit has been filed against Ardent Health, Inc. (NYSE: ARDT) and certain officers for alleged violations of federal securities laws.
- The lawsuit covers investors who purchased Ardent securities between July 18, 2024, and November 12, 2025.
- The complaint alleges overstated third-quarter 2025 revenue due to inadequate accounts receivable collectability determinations and overstated 2025 EBITDA guidance, which is expected to be reduced by $57.5 million (approximately 9.6%).
- Investors have until March 9, 2026, to request to be appointed as lead plaintiff.
Jan 12, 2026, 5:00 PM
Ardent Health Faces Securities Class Action Lawsuit
ARDT
Legal Proceedings
Accounting Changes
Financial Restatement
- A securities class action lawsuit has been filed against Ardent Health, Inc. (ARDT) following the company's Q3 2025 financial disclosures.
- The lawsuit alleges misleading statements related to significant adverse accounting adjustments totaling approximately $90 million.
- These adjustments included a $42.6 million decrease in revenue due to a change in accounting estimate for accounts receivable collectability and a $47.2 million increase in professional liability reserves.
- The market reacted to this news on November 12, 2025, with Ardent's stock price tumbling over 33%.
- The class period for the lawsuit is between July 18, 2024, and November 12, 2025, with a lead plaintiff deadline of March 9, 2026.
Jan 9, 2026, 7:50 PM
Ardent Health Faces Securities Fraud Lawsuit Following Stock Drop
ARDT
Legal Proceedings
Accounting Changes
Demand Weakening
- Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Ardent Health, Inc. and its senior executives for securities fraud.
- The lawsuit alleges Ardent Health misrepresented its accounts receivable collectability process, claiming "detailed reviews of historical collections" but actually using a "180-day cliff" for full reservation, which allegedly inflated reported receivables and delayed loss recognition.
- This legal action follows a stock drop of over 33% on November 13, 2025, after Ardent Health announced a $43 million decrease in revenue and a $54 million increase in professional liability reserves.
- Investors have until March 9, 2026, to apply to be appointed lead plaintiff in the class action lawsuit.
Jan 8, 2026, 7:24 PM
Hagens Berman Investigates Ardent Health Following $97 Million Accounting Adjustments
ARDT
Legal Proceedings
Accounting Changes
Guidance Update
- Shareholder rights law firm Hagens Berman has initiated an investigation into Ardent Health, Inc. (NYSE: ARDT) for potential securities law violations after the company's Q3 2025 financial disclosures revealed significant adverse accounting adjustments.
- These adjustments totaled $97 million, comprising a $43 million reduction in revenue due to collectability estimates and a $54 million increase in professional liability reserves.
- The disclosures led to Ardent Health's stock price falling over 33%.
- The investigation focuses on whether company leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves, and if these were long-standing issues.
- Additionally, the company made a significant cut to its 2025 Adjusted EBITDA guidance.
Dec 23, 2025, 2:30 PM
Ardent Health Under Investigation Following Q3 2025 Financial Disclosures
ARDT
Financial Restatement
Accounting Changes
Legal Proceedings
- Hagens Berman has launched an investigation into Ardent Health, Inc. (ARDT) following its Q3 2025 financial disclosures on November 12, 2025.
- The investigation focuses on adverse accounting adjustments totaling $97 million, which led to the stock plummeting over 33%.
- These adjustments include a $43 million revenue reduction related to collectability estimates and a $54 million increase in professional liability reserves.
- The firm is examining whether Ardent's leadership failed to disclose material weaknesses in internal controls concerning revenue recognition and liability reserves, alongside a significant cut to 2025 Adjusted EBITDA guidance.
Dec 16, 2025, 5:27 AM
Hagens Berman Investigates Ardent Health Over Accounting Adjustments
ARDT
Accounting Changes
Legal Proceedings
Guidance Update
- Shareholder rights law firm Hagens Berman has initiated an investigation into Ardent Health (ARDT) following the company's Q3 2025 financial disclosures.
- The investigation focuses on $97 million in adverse accounting adjustments, which include a $43 million revenue reduction and a $54 million increase in professional liability reserves.
- These disclosures, made on November 12, 2025, caused Ardent Health's stock to tumble over 33%.
- Hagens Berman is scrutinizing whether company leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves, and the subsequent significant cut to 2025 Adjusted EBITDA guidance.
Dec 11, 2025, 2:30 PM
Quarterly earnings call transcripts for Ardent Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more